In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds.

AUTOR(ES)

Del Poeta, M

RESUMO

The in vitro activity of the new antifungal drug pneumocandin L-743,872 against 55 isolates of clinically important molds was examined by an adapted macrobroth dilution method for yeasts. Pneumocandin L-743,872 exhibited in vitro antifungal activity against Alternaria sp., Aspergillus flavus, Aspergillus fumigatus, Curvularia lunata, Exophiala jeanselmei, Fonsecaea pedrosoi, Paecilomyces variotii, and Scedosporium apiospermum. The drug appeared to lack significant in vitro inhibitory activity against Fusarium oxysporum, Fusarium solani, Rhizopus arrhizus, Paecilomyces lilacinus, and Scedosporium prolificans.

Documentos Relacionados

• Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro.
• In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species.
• In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872).
• Efficacy of MK-991 (L-743,872), a Semisynthetic Pneumocandin, in Murine Models of Pneumocystis carinii
• Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872).